Paper28487385
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A and 19 others. Cancer Res, 2017. Cited by 354 papers, by iCite.
Cite this record
ConductScience Library. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Papers, record 28487385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28487385
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Head and Neck Neoplasms | Major topic |
| Lung Neoplasms | Major topic |
| Melanoma | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Gene Expression | |
| Gene Expression Profiling | |
| Humans | |
| Male | |
| Middle Aged | |
| Nivolumab | |
| Squamous Cell Carcinoma of Head and Neck |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 29268478 | The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy. | https://conductscience.org/library/papers/29268478 |
Source PubMed
Cited by284
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 354 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42963427 | GALE is a tumor-intrinsic checkpoint of Vγ9Vδ2 T cell-mediated killing. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42963427 | PubMed |
| 42903351 | Variant-informed multimodal tissue-state modeling reveals an NRF2 stress niche and dependency axis in KEAP1/NFE2L2-altered cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903351 | PubMed |
| 42780548 | The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42780548 | PubMed |
| 42771495 | Key regulatory elements of the TGFβ-LRRC15 axis predict disease progression and immunotherapy resistance across cancer types. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/42771495 | PubMed |
| 42731874 | Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42731874 | PubMed |
| 42409796 | Tumor-draining lymph nodes shape the tumor microenvironment through enrichment of tumor-reactive effector-exhausted CD8+ T cells. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42409796 | PubMed |
| 42326763 | Deciphering the Heterogeneous Microenvironment of Head and Neck Squamous Cell Carcinoma Through an Integrated Immune Inflammation Framework. | Int J Genomics | 2026 | https://conductscience.org/library/papers/42326763 | PubMed |
| 42258951 | An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy. | EBioMedicine | 2026 | https://conductscience.org/library/papers/42258951 | PubMed |
| 42215484 | GraphTME: graph-based framework for predicting immunotherapy response by interpreting tumour microenvironment interactions using spatial transcriptomics. | NPJ Syst Biol Appl | 2026 | https://conductscience.org/library/papers/42215484 | PubMed |
| 42189121 | IKKβ and USP28 Regulate HEY1 Stability to Promote Cancer Stemness and Immune Evasion in Hepatocellular Carcinoma. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42189121 | PubMed |
| 42141174 | CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8+ T cells. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42141174 | PubMed |
| 42034709 | Profiling the tumor immunological status in Japanese solid cancers using the tumor immune status scoring algorithm. | Sci Rep | 2026 | https://conductscience.org/library/papers/42034709 | PubMed |
| 42000944 | GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42000944 | PubMed |
| 41961149 | Post-translational modification signature shapes the tumor immune microenvironment and predicts clinical outcomes in melanoma. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41961149 | PubMed |
| 41745118 | Targeting Telomerase in Cancer: Vaccine-Based Strategies, Clinical Evidence, and Synergy with Immunotherapy. | Diseases | 2026 | https://conductscience.org/library/papers/41745118 | PubMed |
| 41706852 | R-loop processing via REXO4-RNaseH1-mediated endo- and exo-cleavage coupling mode prevents genome instability and antitumor immunity. | Sci Adv | 2026 | https://conductscience.org/library/papers/41706852 | PubMed |
| 41663422 | CD38 degrades MAVS through mitophagy to inhibit type I interferon secretion in nasopharyngeal carcinoma cells and impairs CD8+T cell-mediated anti-tumor immunity. | Nat Commun | 2026 | https://conductscience.org/library/papers/41663422 | PubMed |
| 41376899 | Single-cell and spatial transcriptome landscapes reveal the spatial immune defense pattern shared by primary and brain metastatic lung adenocarcinoma. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/41376899 | PubMed |
| 41293150 | A tumor immune microenvironment gene expression signature for predicting prognosis, immunotherapy efficacy, and drug candidates in triple-negative breast cancer. | Front Immunol | 2025 | https://conductscience.org/library/papers/41293150 | PubMed |
| 41243951 | PRECOG update: an augmented resource of clinical outcome associations with gene expression for adult, pediatric, and immunotherapy cohorts. | Nucleic Acids Res | 2026 | https://conductscience.org/library/papers/41243951 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| IFNA1 | 3439 | PubTator's text mining | https://conductscience.org/library/genes/3439 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28487385
GET https://conductscience.org/api/papers/v1/28487385/cited_by?page=2